Communiqués Palvella Therapeutics, Inc.

Actions

PVLA

US6979471090

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 14/08/2026			Varia. 5j.	Varia. 1 janv.
156,13 ^USD	-0,27%		-1,04%	+49,16%

04/08	Transcript : Palvella Therapeutics, Inc., Q2 2026 Earnings Call, Aug 04, 2026
04/08	Palvella Therapeutics : creusement de la perte nette au deuxième trimestre	MT

Communiqués

05/08	Palvella Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference	AQ
04/08	Palvella Therapeutics: Q2 Earnings Snapshot	AQ
04/08	Palvella Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update	AQ
30/07	Palvella Therapeutics Chief Scientific Officer Jeff Martini, Ph.D. Selected to Present at Upcoming FDA Public Workshop on Drug Repurposing	AQ
28/07	Palvella Therapeutics to Host Second Quarter 2026 Financial Results and Corporate Update Conference Call on August 4, 2026	AQ
30/06	Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors	AQ
29/06	Palvella Therapeutics Submits First Module of Rolling New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations	AQ
23/06	FDA Grants Rolling Review of Palvella's QTORIN Rapamycin NDA for Microcystic Lymphatic Malformations	AQ
22/06	FDA Grants Rolling Review of Palvella’s QTORIN™ Rapamycin NDA for Microcystic Lymphatic Malformations	AQ
03/06	Palvella Therapeutics Announces Completion of FDA Pre-NDA Meeting for QTORIN™ Rapamycin in Microcystic Lymphatic Malformations	AQ
03/06	Palvella Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026	AQ
02/06	Palvella Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026	AQ
27/05	Palvella Therapeutics Strengthens QTORIN™ Pitavastatin Intellectual Property with Yale-Licensed U.S. Patent Providing Protection into 2043	AQ
21/05	Palvella Therapeutics Named Healthcare & Life Sciences Company of the Year at the Philadelphia Alliance for Capital and Technologies (PACT) Ecosystem Awards	AQ
20/05	Palvella Therapeutics Presents New SELVA and TOIVA Data at the 2026 International Society for the Study of Vascular Anomalies World Congress Supporting QTORIN™ Rapamycin as a Potential First-in-Disease Therapy for Multiple Serious, Rare Vascular Malformations	AQ
18/05	Palvella Therapeutics Announces New Data from the Phase 2 TOIVA Trial of QTORIN Rapamycin in Cutaneous Venous Malformations Presented at the 83rd Annual Meeting of the Society for Investigative Dermatology	AQ
15/05	Palvella Therapeutics Announces New Data from the Phase 2 TOIVA Trial of QTORIN™ Rapamycin in Cutaneous Venous Malformations Presented at the 83rd Annual Meeting of the Society for Investigative Dermatology	AQ
13/05	Palvella Therapeutics Announces Uplisting to the Nasdaq Global Market	AQ
07/05	Palvella Therapeutics: Q1 Earnings Snapshot	AQ
07/05	Palvella Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update	AQ
04/05	Palvella Therapeutics Announces First Patients Dosed in Phase 2 LOTU Trial of Fast Track-Designated QTORIN™ Rapamycin for Clinically Significant Angiokeratomas	AQ
30/04	Palvella Therapeutics to Host First Quarter 2026 Financial Results and Corporate Update Conference Call on May 7, 2026	AQ
20/04	Palvella Therapeutics to Present QTORIN™ Rapamycin Results from Phase 3 SELVA and Phase 2 TOIVA Studies at the International Society for the Study of Vascular Anomalies World Congress 2026	AQ
13/04	Palvella Therapeutics Appoints John D. Doux, M.D., M.B.A., Dermatologist and Recognized Leader in Rare Skin Diseases, to Board of Directors	AQ
31/03	Palvella Therapeutics: Q4 Earnings Snapshot	AQ